Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice

Y. van Gemert, A. E. Kozijn, M. G. Pouwer, N. N.L. Kruisbergen, M. H.J. van den Bosch, A.B. Blom, E. J. Pieterman, H. Weinans, R. Stoop, H. M.G. Princen, P. L.E.M. van Lent*

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

7 Citations (Scopus)
27 Downloads (Pure)

Abstract

Objective: High systemic cholesterol levels have been associated with osteoarthritis (OA) development. Therefore, cholesterol lowering by statins has been suggested as a potential treatment for OA. We investigated whether therapeutic high-intensive cholesterol-lowering attenuated OA development in dyslipidemic APOE∗3Leiden.CETP mice. Methods: Female mice (n = 13–16 per group) were fed a Western-type diet (WTD) for 38 weeks. After 13 weeks, mice were divided into a baseline group and five groups receiving WTD alone or with treatment: atorvastatin alone, combined with PCSK9 inhibitor alirocumab and/or ANGPTL3 inhibitor evinacumab. Knee joints were analysed for cartilage degradation, synovial inflammation and ectopic bone formation using histology. Aggrecanase activity in articular cartilage and synovial S100A8 expression were determined as markers of cartilage degradation/regeneration and inflammation. Results: Cartilage degradation and active repair were significantly increased in WTD-fed mice, but cholesterol-lowering strategies did not ameliorate cartilage destruction. This was supported by comparable aggrecanase activity and S100A8 expression in all treatment groups. Ectopic bone formation was comparable between groups and independent of cholesterol levels. Conclusions: Intensive therapeutic cholesterol lowering per se did not attenuate progression of cartilage degradation in dyslipidemic APOE∗3Leiden.CETP mice, with minor joint inflammation. We propose that inflammation is a key feature in the disease and therapeutic cholesterol-lowering strategies may still be promising for OA patients presenting both dyslipidemia and inflammation.

Original languageEnglish
Pages (from-to)1314-1323
JournalOsteoarthritis and Cartilage
Volume29
Issue number9
DOIs
Publication statusPublished - 2021

Keywords

  • Cholesterol
  • Dyslipidemia
  • Mouse model
  • Osteoarthritis (OA)
  • Western-type diet

Fingerprint

Dive into the research topics of 'Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice'. Together they form a unique fingerprint.

Cite this